Under the direction of Drs. Shelton Earp, Charles Perou, and Lisa Carey, SPORE PI and Co-PIs, the Administration Core supports the UNC Breast Cancer SPORE's overall scientific/ translational goals by providing leadership and, with the help of superb staff, day-to-day administration. The Core organizes intra and inter-SPORE interactions;administrative/scientific oversight of all research projects, cores, and developmental programs;interaction with NCI and the SPORE program;and planning and evaluation activities. This Core also monitors SPORE expenditures and addresses grant management issues. Like the SPORE itself, the Administration Core blends experienced and stable leadership with new expertise, energy, and perspective. Because the SPORE PI Dr. Earp is also Cancer Center Director, this Administration Core links the Breast SPORE to the UNC Lineberger Comprehensive Cancer Center and its other large translational efforts (e.g. DoD Prostate Cancer Center of Excellence, Center of Cancer Nanotechnology Excellence, the Cancer Genome Atlas), as well as to the University, School of Medicine, and Hospital administration.

Public Health Relevance

The Administration Core supports the five projects and core resources that will continue to explore the effect of intrinsic subtype on the predisposition, progression, and therapeutic resistance of difficult-to-treat breast cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-21
Application #
8723750
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
21
Fiscal Year
2014
Total Cost
$60,610
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ruiz-Narváez, Edward A; Haddad, Stephen A; Lunetta, Kathryn L et al. (2016) Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium. Breast Cancer Res Treat 155:355-63
Cheng, Ting-Yuan David; Ambrosone, Christine B; Hong, Chi-Chen et al. (2016) Genetic variants in the mTOR pathway and breast cancer risk in African American women. Carcinogenesis 37:49-55
Murphy, Caitlin C; Sandler, Robert S; Sanoff, Hanna K et al. (2016) Decrease in Incidence of Colorectal Cancer Among Individuals 50 Years or Older After Recommendations for Population-based Screening. Clin Gastroenterol Hepatol :
Sun, Xuezheng; Nichols, Hazel B; Tse, Chiu-Kit et al. (2016) Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype. Cancer Epidemiol Biomarkers Prev 25:60-7
Li, Hui; Zhu, Yitan; Burnside, Elizabeth S et al. (2016) Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer 2:
Nichols, Hazel B; Bowles, Erin J A; Islam, Jessica et al. (2016) Tamoxifen Initiation After Ductal Carcinoma In Situ. Oncologist 21:134-40
He, Zhijian; Wan, Xiaomeng; Schulz, Anita et al. (2016) A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials 101:296-309
Johnson, Amy R; Qin, Yuanyuan; Cozzo, Alyssa J et al. (2016) Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation. Mol Metab 5:506-26
Roberts, Megan C; Weinberger, Morris; Dusetzina, Stacie B et al. (2016) Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. J Clin Oncol 34:130-8
Hertz, Daniel L; Deal, Allison; Ibrahim, Joseph G et al. (2016) Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. Oncologist 21:795-803

Showing the most recent 10 out of 500 publications